number
patient
present
emerg
depart
ed
meticillinresist
staphylococcu
aureu
mrsa
increas
studi
focu
patient
bacteraemia
januari
june
clinic
characterist
outcom
consecut
patient
mrsa
bacteraemia
visit
ed
univers
hospit
studi
averag
age
patient
year
healthcareassoci
mrsa
bacteraemia
compris
case
catheterrel
bacteraemia
common
type
infect
follow
soft
tissu
infect
primari
bacteraemia
differ
type
infect
significantli
relat
differ
outcom
inhospit
mortal
mortal
decreas
patient
rapidli
fatal
diseas
mortal
within
day
exclud
isol
exhibit
lower
suscept
vancomycin
minimum
inhibitori
concentr
mic
gml
factor
associ
mortal
includ
sever
underli
ill
sever
bacteraemia
persist
bacteraemia
detriment
effect
elev
mic
could
demonstr
despit
appli
sever
definit
patient
outcom
patient
admit
ed
mrsa
bacteraemia
carri
high
overal
mortal
howev
sever
underli
ill
sever
bacteraemia
persist
bacteraemia
correl
mortal
vancomycin
mic
gml
mrsa
isol
number
patient
present
emerg
depart
ed
meticillinresist
staphylococcu
aureu
mrsa
infect
increas
studi
focu
patient
bacteraemia
taiwan
preval
mrsa
amongst
nosocomi
staphylococc
infect
ca
mrsa
emerg
communityacquir
pathogen
previou
studi
patient
ed
mrsa
bacteraemia
patient
true
commun
mrsa
bacteraemia
rare
seen
howev
recent
year
number
patient
increas
hospit
concern
mrsa
bacteraemia
due
poor
respons
glycopeptid
treatment
mani
factor
report
close
associ
poor
respons
includ
sever
ill
type
infect
persist
bacteraemia
notabl
increas
minimum
inhibitori
concentr
mic
mrsa
isol
mani
patient
mrsa
bacteraemia
complex
underli
ill
develop
bacteraemia
prolong
hospit
stay
thu
interest
outcom
patient
mrsa
bacteraemia
treat
ed
despit
studi
suggest
blood
cultur
order
adult
ed
rare
clinic
use
mrsa
bacteraemia
detect
ed
would
usual
chang
antimicrobi
agent
hospit
empir
glycopeptid
use
recommend
moreov
bacteraemia
recov
ed
usual
less
complic
compar
nosocomi
bacteraemia
howev
patient
might
receiv
complet
examin
rapid
mortal
occur
increas
mrsa
bacteraemia
aris
commun
describ
result
observ
studi
mrsa
bacteraemia
univers
hospit
ed
focus
risk
factor
poor
patient
outcom
nation
taiwan
univers
hospit
ntuh
academ
affili
medic
centr
provid
primari
tertiari
care
northern
taiwan
annual
ed
censu
record
visit
januari
may
prospect
studi
initi
patient
age
year
posit
aureu
blood
cultur
within
h
arriv
ed
studi
discontinu
due
epidem
sever
acut
respiratori
syndrom
restart
juli
patient
evalu
use
structur
record
form
complet
whole
pictur
mrsa
bacteraemia
ntuh
ed
data
patient
mrsa
bacteraemia
retrospect
collect
form
june
june
thu
patient
mrsa
bacteraemia
present
ed
januari
june
incorpor
studi
patient
hospitalis
h
discharg
hospit
within
h
consid
nosocomi
bacteraemia
healthcareassoci
bacteraemia
includ
bacteraemia
relat
receiv
haemodialysi
chemotherapi
parenter
nutrit
outpati
basi
nurs
home
stay
recent
surgeri
prior
hospitalis
within
year
bacteraemia
patient
without
risk
exposur
mention
defin
commun
acquir
clinic
cours
primari
site
bacteraemia
evalu
accord
inform
suppli
primari
care
physician
medic
record
diagnosi
infect
focu
bacteraemia
base
clinic
bacteriolog
radiolog
investig
infect
endocard
ie
defin
modifi
duke
criteria
catheterrel
bacteraemia
crbsi
defin
posit
semiquantit
tip
cultur
colonyform
unit
andor
high
clinic
suspicion
although
differenti
time
posit
appli
owe
time
posit
routin
record
pneumonia
defin
posit
cultur
mrsa
purul
sputum
sampl
presenc
newli
develop
lung
infiltr
urinari
tract
infect
uti
defin
posit
urin
cultur
pyuria
orthopaed
infect
includ
osteomyel
document
patholog
imag
studi
compat
clinic
find
prosthet
joint
infect
septic
arthriti
andor
posit
microbiolog
result
obtain
accord
current
suggest
soft
tissu
infect
sti
defin
clinic
soft
tissu
inflamm
plu
bacteraemia
primari
focu
could
identifi
bacteraemia
classifi
primari
follow
data
record
patient
age
sex
underli
ill
sever
ill
classifi
mccabejackson
criteria
sever
bacteraemia
assess
pitt
bacteraemia
score
septic
shock
persist
bacteraemia
defin
posit
blood
cultur
day
glycopeptid
treatment
instal
foreign
bodi
includ
prosthet
joint
pacemak
intravenousfoley
cathet
debrid
includ
catheterforeign
bodi
remov
surgic
debrid
infect
tissu
metastat
infect
includ
document
mrsa
infect
remot
origin
site
inact
malign
includ
underli
ill
patient
admit
ntuh
telephon
contact
perform
collect
requir
inform
use
glycopeptid
prior
knowledg
blood
cultur
result
defin
empir
therapi
glycopeptid
use
either
vancomycin
teicoplanin
suggest
regimen
treat
mrsa
infect
institut
linezolid
control
infecti
diseas
physician
addit
earli
initi
empir
glycopeptid
treatment
encourag
institut
adjust
vancomycin
dosag
achiev
trough
level
gml
suggest
monitor
clinic
pharmacist
sever
endpoint
use
evalu
outcom
patient
includ
inhospit
mortal
mortal
mortal
exclud
patient
die
within
day
patient
mccabe
rapidli
fatal
diseas
patient
mortal
relat
mrsa
bacteraemia
blood
cultur
specimen
inocul
bactec
bactec
plu
cultur
bottl
use
bactec
system
becton
dickinson
spark
identif
aureu
base
morpholog
coloni
grown
trypticas
soy
agar
supplement
sheep
blood
bbl
microbiolog
system
cockeysvil
md
result
gram
stain
posit
slide
tube
coagulas
test
suscept
antimicrobi
agent
determin
standard
disk
diffus
method
sinc
g
cefoxitin
disk
bbl
microbiolog
system
appli
detect
mrsa
clinic
isol
mrsa
collect
store
c
trypticas
soy
broth
difco
laboratori
detroit
mi
supplement
glycerol
mic
vancomycin
teicoplanin
linezolid
daptomycin
determin
broth
microdilut
method
mrsa
isol
sever
endpoint
patient
outcom
use
evalu
factor
relat
poor
prognosi
amongst
patient
mrsa
bacteraemia
recov
ed
mean
januari
june
total
patient
present
ntuh
ed
mrsa
bacteraemia
includ
clinic
characterist
patient
summaris
crbsi
common
type
infect
follow
sti
primari
bacteraemia
lower
respiratori
tract
infect
orthopaed
infect
ie
uti
endovascular
infect
ie
biliari
infect
common
underli
ill
diabet
mellitu
renal
insuffici
intraven
cathet
use
patient
inhospit
mortal
rate
associ
increas
age
persist
bacteraemia
polymicrobi
bacteraemia
fewer
debrid
rapidli
fatal
diseas
accord
mccabe
classif
higher
pitt
bacteraemia
score
septic
shock
lower
respiratori
tract
infect
activ
malign
metastat
infect
tabl
analysi
patient
die
within
day
reveal
similar
set
risk
factor
well
lower
mortal
rate
amongst
patient
stiassoci
bacteraemia
differ
mortal
rate
amongst
differ
type
infect
signific
inhospit
mortal
bacteraemia
due
lower
respiratori
tract
infect
carri
highest
mortal
whilst
bacteraemia
secondari
orthopaed
infect
carri
lowest
mortal
rate
amongst
differ
type
infect
shown
fig
explor
efficaci
treatment
respons
patient
die
within
day
ed
visit
n
mccabe
rapidli
fatal
diseas
n
mortal
relat
mrsa
bacteraemia
n
exclud
exclud
patient
patient
remain
inhospit
mortal
group
tabl
fewer
risk
factor
associ
mortal
identifi
group
includ
increas
age
persist
bacteraemia
ultim
fatal
diseas
nonfat
diseas
accord
mccabe
classif
higher
pitt
bacteraemia
score
septic
shock
lower
respiratori
tract
infect
metastat
infect
logist
regress
analysi
mortal
group
reveal
age
p
odd
ratio
confid
interv
ci
persist
bacteraemia
p
ci
ultim
fatal
diseas
p
ci
pitt
bacteraemia
score
p
ci
signific
risk
factor
mortal
associ
metastat
infect
mortal
borderlin
signific
p
ci
empir
glycopeptid
therapi
associ
decreas
mortal
mrsa
isol
suscept
vancomycin
teicoplanin
linezolid
daptomycin
tabl
mic
vancomycin
mrsa
isol
gml
gml
detriment
effect
increas
vancomycin
mic
patient
outcom
could
demonstr
despit
separ
analys
use
differ
definit
outcom
intraven
linezolid
use
six
patient
later
cours
hospitalis
four
due
treatment
failur
glycopeptid
two
due
cytopenia
use
glycopeptid
oral
linezolid
prescrib
three
patient
follow
glycopeptid
therapi
oral
switch
studi
mrsa
bacteraemia
includ
nosocomi
acquir
case
compar
differ
mrsa
meticillinsuscept
aureu
mssa
ever
antimicrobi
agent
use
mssa
mrsa
differ
studi
focus
patient
mrsa
bacteraemia
recov
ed
demonstr
characterist
outcom
patient
outcom
patient
close
associ
sever
underli
ill
bacteraemia
age
persist
bacteraemia
despit
recent
studi
suggest
increas
mic
mrsa
isol
detriment
effect
patient
outcom
support
current
studi
inhospit
mortal
amongst
patient
mrsa
isol
vancomycin
mic
gml
gml
respect
mani
factor
complic
evalu
treatment
respons
patient
mrsa
bacteraemia
one
import
factor
wide
variat
sever
underli
ill
patient
rapidli
fatal
diseas
carri
highest
mortal
rate
bacteraemia
episod
reach
studi
previou
one
inclus
patient
surviv
analys
confound
search
import
prognost
factor
recent
studi
also
found
underli
ill
import
predictor
mortal
patient
aureu
bacteraemia
type
infect
also
clearli
correl
treatment
respons
differ
type
infect
determin
feasibl
sourc
infect
control
pneumonia
long
consid
difficult
type
mrsa
infect
treat
difficulti
achiev
high
concentr
glycopeptid
lung
remov
infect
tissu
might
repres
equal
import
obstacl
effect
manag
studi
mortal
rate
patient
orthopaed
infect
substanti
lower
pneumon
patient
probabl
due
rel
lower
comorbid
patient
eas
surgic
intervent
spectrum
mrsa
bacteraemia
vari
mild
lifethreaten
diseas
howev
determin
type
infect
sometim
difficult
especi
patient
earli
mortal
without
novel
molecular
method
patient
mrsa
bacteraemia
surviv
sever
day
wait
posit
blood
cultur
tradit
identif
isol
determin
antimicrobi
suscept
order
confirm
exist
mrsa
also
take
day
vancomycin
take
effect
patient
studi
die
cultur
result
known
shown
mortal
rate
recent
studi
show
empir
glycopeptid
might
improv
outcom
patient
mrsa
infect
howev
amongst
patient
die
within
day
studi
rapidli
fatal
diseas
averag
pitt
bacteraemia
score
impli
patient
advanc
diseas
outcom
might
alter
earli
antimicrobi
therapi
studi
period
linezolid
avail
altern
agent
mrsa
infect
quinupristindalfopristin
market
taiwan
studi
linezolid
use
nine
patient
four
die
despit
linezolid
use
role
combin
therapi
high
rate
gentamicin
resist
also
found
amongst
mrsa
isol
taiwan
despit
occasion
use
gentamicin
amongst
patient
routin
clinic
practic
previou
report
show
ad
rifampicin
effect
combin
therapi
mrsa
infect
resist
mrsa
rifampicin
taiwan
high
howev
agent
use
initi
treatment
patient
hospit
increas
rate
mrsa
isol
high
vancomycin
mic
seriou
import
issu
increas
vancomycin
mic
isol
correl
rate
treatment
failur
although
vancomycin
mic
within
suscept
rang
howev
studi
despit
sever
endpoint
appli
correl
increas
vancomycin
mic
poor
patient
outcom
found
recent
studi
soriano
et
al
show
elev
mic
alter
patient
mortal
vancomycin
mic
gml
carri
higher
risk
death
patient
receiv
empir
therapi
may
explan
discrep
first
patient
studi
sakoula
et
al
identifi
poor
respons
vancomycin
therapi
wherea
studi
includ
patient
clinic
signific
mrsa
bacteraemia
present
ed
second
distribut
vancomycin
mic
mrsa
isol
rel
homogen
high
present
studi
gml
might
limit
abil
demonstr
probabl
benefici
effect
lower
mic
third
percentag
empir
therapi
low
studi
owe
limit
number
could
reproduc
find
soriano
et
al
summari
studi
patient
mrsa
bacteraemia
treat
ed
found
effect
increas
vancomycin
mic
isol
patient
outcom
patient
mrsa
isol
rel
high
vancomycin
mic
outcom
close
associ
sever
underli
ill
bacteraemia
age
persist
bacteraemia
whether
empir
vancomycin
therapi
new
antimrsa
agent
improv
outcom
patient
deserv
research
fund
fund
sourc
compet
interest
none
declar
ethic
approv
institut
review
board
nation
taiwan
univers
hospit
taipei
taiwan
